FABP7 Inhibition Targets Glioblastoma Microtubes: Preclinical Clues to Disrupting Developmental Hijacking in the Brain's Deadliest Tumor

The University of Alberta team's 2025 Neuro-Oncology study used human glioblastoma cell cultures and orthotopic mouse models to show that brain fatty acid-binding protein 7 (FABP7), re-expressed in tumor microtubes, drives directional infiltration and therapy resistance. This work builds on Osswald et al. (Nature 2015), which first characterized tumor microtubes as a resistance network in patient-derived xenografts, but extends the mechanistic link to a developmental protein co-opted by glioma stem-like cells. Unlike the original MedicalXpress summary, the Alberta experiments demonstrate that pharmacologic FABP7 blockade not only collapses microtube networks in vitro but also extends median survival in mice by approximately 30% while restoring temozolomide sensitivity; however, the study remains strictly preclinical, with no randomized data and modest cohort sizes typical of early xenograft work. A 2023 review in Cancer Cell by Dirkse and colleagues further contextualizes these findings by noting that microtube formation correlates with mesenchymal subtype dominance and poor prognosis across TCGA datasets, underscoring why targeting FABP7 could address a gap left by standard Stupp-protocol therapies. Limitations include unknown off-target effects of the inhibitor in normal neural progenitors and the absence of combination data with radiotherapy in larger cohorts. No conflicts of interest were declared.